BioMarin Pharmaceutical (BMRN) : $2.12 million worth of transactions were on upticks in BioMarin Pharmaceutical (BMRN), compared to $1.25 million on downticks. The ratio between the two was 1.7, whereas, the net money flow stood at a healthy $0.87 million on Fridays session. The consistent buying on upticks in the stock accounted for $0million worth of trades. The total money flow into the stock stood at $0 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.69%. The stock was trading at $94.54, with a drop of $0.66 over the previous days close. The stock recorded -1.75% for the week.
The company Insiders own 2.5% of BioMarin Pharmaceutical shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -4.38% . Institutional Investors own 93.13% of BioMarin Pharmaceutical shares. During last six month period, the net percent change held by insiders has seen a change of -13.99%.
In a related news, The officer (EVP, Chief Medical Officer), of Biomarin Pharmaceutical Inc, Fuchs Henry J had unloaded 15,000 shares at $95.06 per share in a transaction on August 26, 2016. The total value of transaction was $1,425,900. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
BioMarin Pharmaceutical (NASDAQ:BMRN): The stock opened at $95.3 and touched an intraday high of $96.49 on Friday. During the day, the stock corrected to an intraday low of $93.86, however, the bulls stepped in and pushed the price higher to close in the green at $95.73 with a gain of 0.57% for the day. The total traded volume for the day was 801,788. The stock had closed at $95.19 in the previous trading session.
BioMarin Pharmaceutical (BMRN) : During the past 4 weeks, traders have been relatively bearish on BioMarin Pharmaceutical (BMRN), hence the stock is down -3.12% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.01% relative to the S&P 500. The 4-week change in the price of the stock is -3.24% and the stock has fallen -0.51% in the past 1 week.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).